FGFR2 and neoplasm: Ongoing clinical trials and agnostic therapies have also suggested that emerging biomarkers, such as fibroblast growth factor receptor 2 (FGFR2) and neurotrophic tyrosine receptor kinase (NTRK) fusions/rearrangements, as well as tumor mutational burden (TMB), will be added to the list of biomarkers to be tested in the daily clinical practice before the decision-making therapy of advanced GC.